Compare Neurocrine Biosciences Inc (NBIX) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while First Trust NASDAQ 100 Technology Index Fund trades at $329.55 (market cap $4.15B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.5× First Trust NASDAQ 100 Technology Index Fund's market cap, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| NBIX | QTEC | |
|---|---|---|
Market Cap | $14.60B | $4.15B |
Volume | 1,075,694 | 278,646 |
Sector | Health | Broad Market / Factor |
52-Week High | $185.50 | $340.28 |
52-Week Low | $123.10 | $207.03 |
Typical Hold Time | 23 Days | 40 Days |
Enterprise Value | $14.61B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
QTEC trades at $335.82, down 1.31% today, with a bullish technical signal from moving averages but bearish oscillators. The ETF provides equal-weighted exposure to NASDAQ-100 technology stocks, offering diversification across software and hardware sectors. Recent analysis highlights software industry undervaluation relative to historical averages, positioning QTEC as a liquid alternative to similar funds.
The outlook remains cautiously optimistic given technology sector growth potential, though overbought RSI levels suggest near-term consolidation. Key risks include sector volatility and macroeconomic pressures on tech valuations, while institutional interest supports long-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
